SynBiotic SE (ETR:SBX)
3.050
-0.080 (-2.56%)
Apr 24, 2025, 5:36 PM CET
SynBiotic SE Revenue
In the year 2023, SynBiotic SE had annual revenue of 3.86M EUR, down -52.71%. SynBiotic SE had revenue of 3.55M in the quarter ending June 30, 2024.
Revenue
3.86M
Revenue Growth
-52.71%
P/S Ratio
5.50
Revenue / Employee
70.21K
Employees
55
Market Cap
21.24M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Merck KGaA | 21.16B |
Siemens Healthineers AG | 22.67B |
Fresenius SE & Co. KGaA | 21.83B |
Bayer Aktiengesellschaft | 46.61B |
Sartorius Aktiengesellschaft | 3.44B |
Fresenius Medical Care AG | 19.34B |
Carl Zeiss Meditec AG | 2.08B |
Fielmann Group AG | 2.16B |
SynBiotic SE News
- 6 weeks ago - EQS-News: Quo vadis legalisation: SYNBIOTIC and GOC NEXUS at the International Cannabis Business Conference (ICBC) in Berlin - Wallstreet:Online
- 3 months ago - EQS-News: SYNBIOTIC with four new investments in 2024: Further acquisitions in sight for 2025 - Wallstreet:Online
- 4 months ago - EQS-News: Trend-setting decontamination: SYNBIOTIC and GOC NEXUS set the gold standard for cannabis - Wallstreet:Online
- 5 months ago - EQS-News: SYNBIOTIC integrates greensby: Universal platform for the entire hemp and cannabis industry - Wallstreet:Online
- 5 months ago - EQS-News: In full bloom: WEECO Pharma boosts SYNBIOTIC's sales - Wallstreet:Online
- 7 months ago - EQS-News: Share price target 12.50 euros: Annual General Meeting supports SYNBIOTIC's growth plans with over 99 percent approval - Wallstreet:Online
- 7 months ago - Original-Research: SynBiotic SE (von NuWays AG): BUY - Wallstreet:Online
- 7 months ago - SynBiotic transformation: Reaching new operational high(t)s - Wallstreet:Online